Innovative Use of RADA16 Self-Assembling Peptide (PuraBond®) as a Hemostatic Agent in Holmium Laser Enucleation of the Prostate (HoLEP): A Safety and Feasibility Study
Abstract
Hemostasis is a critical aspect of holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia (BPH). While HoLEP offers superior outcomes compared to traditional techniques, effective intraoperative and postoperative bleeding control remains a challenge. This report evaluates the feasibility and safety of PuraBond® (3-D Matrix, Ltd., Chiyoda-ku, Tokyo), a self-assembling peptide (SAP) hemostatic agent, as an adjunct for hemostasis during HoLEP. A single case study was conducted in August 2024 on a 62-year-old male presenting with lower urinary tract symptoms (LUTSs) and a significantly enlarged prostate (152 cc). The patient underwent en-bloc low-power HoLEP under general anesthesia. Following enucleation and morcellation, initial hemostasis was achieved using bipolar diathermy, and PuraBond® was applied endoscopically to the prostatic fossa. Postoperatively, continuous bladder irrigation was initiated, and the patient was monitored for complications. The total operative time was 120 minutes, with 66 minutes for enucleation and 14 minutes for morcellation. A total of 147.7 g of prostatic tissue was enucleated. Hemostasis was successfully achieved with the combined use of diathermy and PuraBond®, resulting in clear irrigation effluent immediately postoperatively. The patient was discharged the same day without complications. The urinary catheter was removed nine days later, and the urine remained clear throughout the recovery period. At the 28-day…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.